He also studied telomeres, and his lab discovered an enzyme, TERT (telomerase reverse transcriptase), which is part of the process of restoring telomeres after they are shortened during cell division.[3]
In 1975, Cech completed his PhD in chemistry at the University of California, Berkeley and in the same year, he entered the Massachusetts Institute of Technology where he engaged in postdoctoral research.[5] In 1978, he obtained his first faculty position at the University of Colorado where he lectured undergraduate students in chemistry and biochemistry, and where he remains on the faculty, currently as distinguished professor in the department of biochemistry. In 2000, Cech succeeded Purnell Choppin as president of the Howard Hughes Medical Institute in Maryland. He also continued to head his biochemistry laboratory at the University of Colorado, Boulder. On April 1, 2008, Cech announced that he would step down as the president of HHMI, to return to teaching and research, in spring 2009.[6] Returning to Boulder, Cech became the first executive director of the BioFrontiers Institute, a position he held until 2020. He also taught general chemistry to freshmen.
Cech is the author of The Catalyst: RNA and the Quest to Unlock Life’s Deepest Secrets, published in June 2024.[7]
Research
Cech's main research area is that of the process of transcription in the nucleus of cells. He studies how the genetic code of DNA is transcribed into RNA. In the 1970s, Cech had been studying the splicing of RNA in the unicellular organism Tetrahymena thermophila when he discovered that an unprocessed RNA molecule could splice itself. In 1982, Cech became the first to show that RNA molecules are not restricted to being passive carriers of genetic information – they can have catalytic functions and can participate in cellular reactions.[8] RNA-processing reactions and protein synthesis on ribosomes in particular are catalysed by RNA. RNA enzymes are known as ribozymes and have provided a new tool for gene technology. They also have the potential to provide new therapeutic agents – for example, they have the ability to destroy and cleave invading, viral RNAs.
Cech's second area of research is on telomeres, the structure that protects the ends of chromosomes. Telomeres are shortened with every duplication of DNA, and must be lengthened again. He studies telomerase, the enzyme that copies the telomeric sequences and lengthens them.[8] The active site protein subunits of telomerase comprise a new class of reverse transcriptases, enzymes previously thought to be restricted to viruses and transposable elements. Telomerase is activated in 90% of human cancers. Therefore, a drug that would inhibit its activity could be useful in treating cancer.
